Your browser doesn't support javascript.
loading
Haploinsufficiency of ARFGEF1 is associated with developmental delay, intellectual disability, and epilepsy with variable expressivity.
Thomas, Quentin; Gautier, Thierry; Marafi, Dana; Besnard, Thomas; Willems, Marjolaine; Moutton, Sébastien; Isidor, Bertand; Cogné, Benjamin; Conrad, Solène; Tenconi, Romano; Iascone, Maria; Sorlin, Arthur; Masurel, Alice; Dabir, Tabib; Jackson, Adam; Banka, Siddharth; Delanne, Julian; Lupski, James R; Saadi, Nebal Waill; Alkuraya, Fowzan S; Zahrani, Fatema Al; Agrawal, Pankaj B; England, Eleina; Madden, Jill A; Posey, Jennifer E; Burglen, Lydie; Rodriguez, Diana; Chevarin, Martin; Nguyen, Sylvie; Mau-Them, Frédéric Tran; Duffourd, Yannis; Garret, Philippine; Bruel, Ange-Line; Callier, Patrick; Marle, Nathalie; Denomme-Pichon, Anne-Sophie; Duplomb, Laurence; Philippe, Christophe; Thauvin-Robinet, Christel; Govin, Jérôme; Faivre, Laurence; Vitobello, Antonio.
Afiliação
  • Thomas Q; Inserm UMR1231 team GAD, University of Burgundy and Franche-Comté, Dijon, France. quentin.thomas@chu-dijon.fr.
  • Gautier T; Genetics Center, FHU-TRANSLAD and GIMI Institute, Dijon Bourgogne University Hospital, Dijon, France. quentin.thomas@chu-dijon.fr.
  • Marafi D; Department of Neurology, Dijon Bourgogne University Hospital, Dijon, France. quentin.thomas@chu-dijon.fr.
  • Besnard T; Institute for Advanced Biology, Centre de Recherche UGA, INSERM U1209, CNRS UMR 5309, Site Santé, Allée des Alpes, La Tronche, France.
  • Willems M; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
  • Moutton S; Department of Pediatrics, Faculty of Medicine, Kuwait University, Safat, Kuwait.
  • Isidor B; Service de génétique médicale, CHU Nantes, Nantes, France.
  • Cogné B; Université de Nantes, CNRS, INSERM, l'institut du thorax, Nantes, France.
  • Conrad S; Unité INSERM U 1051, Département de Génétique Médicale, CHRU de Montpellier, Montpellier, France.
  • Tenconi R; Inserm UMR1231 team GAD, University of Burgundy and Franche-Comté, Dijon, France.
  • Iascone M; Genetics Center, FHU-TRANSLAD and GIMI Institute, Dijon Bourgogne University Hospital, Dijon, France.
  • Sorlin A; Service de génétique médicale, CHU Nantes, Nantes, France.
  • Masurel A; Université de Nantes, CNRS, INSERM, l'institut du thorax, Nantes, France.
  • Dabir T; Service de génétique médicale, CHU Nantes, Nantes, France.
  • Jackson A; Université de Nantes, CNRS, INSERM, l'institut du thorax, Nantes, France.
  • Banka S; Service de génétique médicale, CHU Nantes, Nantes, France.
  • Delanne J; Université de Nantes, CNRS, INSERM, l'institut du thorax, Nantes, France.
  • Lupski JR; University of Padova, Laboratorio Genetica Medica Bergamo, Bergamo, Italy.
  • Saadi NW; University of Padova, Laboratorio Genetica Medica Bergamo, Bergamo, Italy.
  • Alkuraya FS; Inserm UMR1231 team GAD, University of Burgundy and Franche-Comté, Dijon, France.
  • Zahrani FA; Genetics Center, FHU-TRANSLAD and GIMI Institute, Dijon Bourgogne University Hospital, Dijon, France.
  • Agrawal PB; Functional Unit of Innovative Diagnosis for Rare Diseases, Dijon Bourgogne University Hospital, Dijon, France.
  • England E; Inserm UMR1231 team GAD, University of Burgundy and Franche-Comté, Dijon, France.
  • Madden JA; Genetics Center, FHU-TRANSLAD and GIMI Institute, Dijon Bourgogne University Hospital, Dijon, France.
  • Posey JE; Medical Genetics Department, Belfast City Hospital, Manchester, UK.
  • Burglen L; Division of Evolution & Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • Rodriguez D; Division of Evolution & Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • Chevarin M; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester, UK.
  • Nguyen S; Inserm UMR1231 team GAD, University of Burgundy and Franche-Comté, Dijon, France.
  • Mau-Them FT; Genetics Center, FHU-TRANSLAD and GIMI Institute, Dijon Bourgogne University Hospital, Dijon, France.
  • Duffourd Y; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
  • Garret P; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA.
  • Bruel AL; Texas Children's Hospital, Houston, TX, USA.
  • Callier P; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
  • Marle N; College of Medicine, University of Baghdad, Baghdad, Iraq.
  • Denomme-Pichon AS; Children Welfare Teaching Hospital, Baghdad, Iraq.
  • Duplomb L; Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
  • Philippe C; Department of Anatomy and Cell Biology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Thauvin-Robinet C; Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
  • Govin J; Divisions of Newborn Medicine and Genetics & Genomics, Manton Center for Orphan Disease Research, Boston, MA, USA.
  • Faivre L; Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Vitobello A; Center for Mendelian Genomics, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Genet Med ; 23(10): 1901-1911, 2021 10.
Article em En | MEDLINE | ID: mdl-34113008
ABSTRACT

PURPOSE:

ADP ribosylation factor guanine nucleotide exchange factors (ARFGEFs) are a family of proteins implicated in cellular trafficking between the Golgi apparatus and the plasma membrane through vesicle formation. Among them is ARFGEF1/BIG1, a protein involved in axon elongation, neurite development, and polarization processes. ARFGEF1 has been previously suggested as a candidate gene for different types of epilepsies, although its implication in human disease has not been well characterized.

METHODS:

International data sharing, in silico predictions, and in vitro assays with minigene study, western blot analyses, and RNA sequencing.

RESULTS:

We identified 13 individuals with heterozygous likely pathogenic variants in ARFGEF1. These individuals displayed congruent clinical features of developmental delay, behavioral problems, abnormal findings on brain magnetic resonance image (MRI), and epilepsy for almost half of them. While nearly half of the cohort carried de novo variants, at least 40% of variants were inherited from mildly affected parents who were clinically re-evaluated by reverse phenotyping. Our in silico predictions and in vitro assays support the contention that ARFGEF1-related conditions are caused by haploinsufficiency, and are transmitted in an autosomal dominant fashion with variable expressivity.

CONCLUSION:

We provide evidence that loss-of-function variants in ARFGEF1 are implicated in sporadic and familial cases of developmental delay with or without epilepsy.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fatores de Troca do Nucleotídeo Guanina / Epilepsia / Haploinsuficiência / Deficiência Intelectual Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Genet Med Assunto da revista: GENETICA MEDICA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fatores de Troca do Nucleotídeo Guanina / Epilepsia / Haploinsuficiência / Deficiência Intelectual Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Genet Med Assunto da revista: GENETICA MEDICA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França